key: cord-0903211-sc0t9gd7
authors: Guthrie, J. L.; Chen, A. J.; Budhram, D. R.; Cronin, K.; Peci, A.; Nelson, P.; Mallo, G. V.; Broukhanski, G.; Murti, M.; Majury, A.; Mazzulli, T.; Allen, V. G.; Patel, S. N.; Kus, J. V.; Tran, V.; Gubbay, J. B.
title: Characteristics of SARS-CoV-2 Testing for Rapid Diagnosis of COVID-19 during the Initial Stages of a Global Pandemic
date: 2020-12-26
journal: nan
DOI: 10.1101/2020.12.23.20231589
sha: 89a1abbbbce2da48a48b4811774bfdc3c5ce1409
doc_id: 903211
cord_uid: sc0t9gd7

Accurate SARS-CoV-2 diagnosis is essential to guide prevention and control of COVID-19. From January 11 - April 22, 2020, Public Health Ontario conducted SARS-CoV-2 testing of 86,942 specimens collected from 80,354 individuals, primarily using real-time reverse-transcription polymerase chain reaction (rRT-PCR) methods. We analyzed test results across specimen types and for individuals with multiple same-day and multi-day collected specimens. Nasopharyngeal compared to throat swabs had a higher positivity (8.8% vs. 4.8%) and an adjusted estimate 2.9 Ct lower (SE=0.5, p<0.001). Same-day specimens showed high concordance (98.8%), and the median Ct of multi-day specimens increased over time. Symptomatic cases had rRT-PCR results with an adjusted estimate 3.0 Ct (SE=0.5, p<0.001) lower than asymptomatic/pre-symptomatic cases. Overall test sensitivity was 84.6%, with a negative predictive value of 95.5%. Molecular testing is the mainstay of SARS-CoV-2 diagnosis and testing protocols will continue to be dynamic and iteratively modified as more is learned about this emerging pathogen.

As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreads globally, specific, rapid, and reliable diagnostic tests are essential to minimise spread through timely contact investigation and isolation of infected individuals. Rapid detection of SARS-CoV-2 by real-time reverse-transcription polymerase chain reaction (rRT-PCR) is currently the standard testing method for coronavirus disease 2019 (COVID- 19) diagnosis (1) . rRT-PCR has been used to detect SARS-CoV-2 from upper respiratory specimens such as nasopharyngeal swabs (NPS), throat swabs (TS), and saliva (2, 3) , lower respiratory specimens such as sputum, bronchoalveolar lavage, and in some cases non-respiratory specimens (4) .

Early studies detected higher viral loads in respiratory over non-respiratory specimens (5) , with NPS currently the recommended specimen type (6) . Viral loads are typically highest early in the course of illness and decrease after approximately 10-14 days following symptom onset, as reflected in rRT-PCR results at or near the limit of detection (6) (7) (8) .

Diagnostic challenges have arisen as SARS-CoV-2 has been detected across a range of disease manifestations, including pre-symptomatic, asymptomatic, and atypical presentations (5, 9, 10) . Presently, there is limited information regarding the association between patient demographics, clinical presentation, viral load and SARS-CoV-2 detection, particularly with respect to serial testing over time.

More studies are needed to inform the optimal protocol for SARS-CoV-2 diagnostic testing.

Here, we examine SARS-CoV-2 molecular-based test performance characteristics and summarize case-level data related to COVID-19 diagnosis. We analyze rRT-PCR test results across different specimens collected over single and multiple days for individuals. As testing protocols have been dynamic and iteratively modified among laboratories, our study findings will inform the further development and refinement of molecular-based testing and related testing algorithms.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 26, 2020. ;  https://doi.org/10.1101/2020.12.23.20231589 doi: medRxiv preprint

As the provincial reference laboratory, Public Health Ontario (PHO) conducts a large proportion of SARS-CoV-2 testing for Ontario, Canada. During the initial stage of the pandemic, all specimens collected from individuals across the province were submitted to PHO. After March 11, 2020, testing in Ontario was decentralized to increase capacity, and a number of hospital and private laboratories implemented SARS-CoV-2 diagnostic testing. Included in this study were all specimens received for SARS-CoV-2 routine testing by PHO from January 11, 2020 through April 22, 2020.

Specimens submitted to PHO included upper respiratory specimens such as nasopharyngeal, nasal, and throat swabs, lower respiratory specimens (e.g. sputum, bronchoalveolar lavage, lung tissue), and non-respiratory specimens (e.g. blood, stool). Upon collection, swabs were placed in transport media and sent to PHO for processing (11) . Initially, collection of 2 specimens from different upper respiratory sites was recommended, which was later revised to a single specimen due to high demand for swabs.

Demographic, epidemiological and clinical data were abstracted from PHO test requisitions. To reflect changing knowledge regarding COVID-19, these requisitions were updated on several occasions (see Supplementary Figure S1 for key changes in testing guidelines). Information was recorded at the time of specimen collection and included demographics, healthcare setting, self-reported symptoms (12) , and reasons for testing such as travel history and contact with a known or probable COVID-19 case. Specimen type was also recorded. It should be noted that initial requisition versions . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 26, 2020. ; https://doi.org/10.1101/2020.12.23.20231589 doi: medRxiv preprint provided a nasopharyngeal checkbox but not a separate nasal swab option, therefore NPS described herein may represent a compilation of nasal, mid-turbinate and NPS specimens.

Several methods of SARS-CoV-2 detection were implemented over the first few months of the pandemic as newly developed tests and platforms became available. Initially, a nested end-point PCR was used targeting the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) gene(13)(Supplementary Appendix I) followed by Sanger sequencing using standard methods. Early specimens were also sent to Canada's National Microbiology Laboratory (NML) for secondary confirmation and supplementary testing using various NML-developed molecular-based assays. Next, an rRT-PCR laboratory developed test (LDT) was used for detection of the Sarbecovirus subgenus envelope (E) gene and/or SARS-CoV-2

RdRp gene based on Corman et al. (14) primer and probe sequences. Interpretation of the LDT rRT-PCR cycle threshold (Ct) was as follows: Ct ≤38 was categorized as detected (positive), 38.1 -39.9 was indeterminate, and a Ct ≥40 was not detected (negative). Initially, the testing algorithm required detection of both targets for laboratory confirmation. This was later revised to single target detection for COVID-19 diagnosis using the E-gene target alone. As of mid-March, to increase laboratory capacity, a commercial rRT-PCR assay, cobas® SARS-CoV-2 (Roche Diagnostics, Germany) was introduced, which includes E-gene and ORF1ab targets. Specimens tested using the cobas® SARS-CoV-2 rRT-PCR assay were reported as detected (positive) or not detected (negative); the manufacturer does not include an indeterminate category. Uninterpretable results for any test method were reported as invalid. For further details of RNA extraction, PCR protocols and test result definitions see Supplementary Appendix I. Ct values reported herein were based on E-gene test results, as this was the common target used in both the LDT and cobas® SARS-CoV-2 rRT-PCR assays.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 26, 2020. ; https://doi.org/10.1101/2020.12.23.20231589 doi: medRxiv preprint

Demographic and clinical information were summarised at an individual-level. For persons with multiple same-day collected specimens, any positive result was considered a positive for that day.

Collection day was counted from the first date (day 1) of specimen(s) collected for an individual. Missing collection dates were substituted with laboratory login dates as the mean difference between these was 1 day (data not shown). A testing episode was defined as the overall result for an individual on a collection day.

All statistical analyses were performed in R (v4.0.2). Categorical variables were summarized using frequency and percentage with comparison of positive and negative test results for study variables measured using the chi-square (χ 2 ) test. Non-normally distributed continuous variables were summarized using median and interquartile range (IQR) with differences assessed using the nonparametric Mann-Whitney U test, and Wilcoxon signed-rank test for paired samples. A generalised linear regression model was used to examine Ct values with standard error (SE) of NPS and TS adjusted for symptom status, age and gender. Unless otherwise stated indeterminate results were counted as positives.

A total of 86,942 specimens with valid test results were collected from 80,354 individuals and received at PHO from January 11, 2020 through April 22, 2020 (Figure 1 ). This represents 47% of the more than 184,000 SARS-CoV-2 laboratory tests completed in Ontario during this period (15) . Overall, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint had international travel history, and 646 (9.5%) had contact with a known or probable COVID-19 case.

Of these reasons, case contact had a higher likelihood for association with a positive result.

Characteristics of persons with invalid results (n=145) can be seen in Supplementary Table S1 .

The number of specimens received for testing increased as the pandemic evolved, with more than 4,000 specimens tested per day on several days in April (Figure 2 ). Supply chain issues limiting the availability of reagents in late-March are reflected in the decreased number of specimens collected and tested at that time. As testing continued, we observed an increase in the proportion of outbreakassociated specimens, and by the study end date, more than 50% of positive specimens were linked to an outbreak investigation (Figure 2 ).

The majority (99.0%, n=86,071) of specimens were tested with a single assay, the largest number of which were tested using the LDT rRT-PCR assay (n=56,928) or cobas® SARS-CoV-2 assay (n=29,141) (Supplementary . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 26, 2020. ; https://doi.org/10.1101/2020.12.23.20231589 doi: medRxiv preprint

Of 86,942 specimens included in the study, 7,538 (8.7%) tested positive for SARS-CoV-2. The median Ct across all assays for the first positive specimen of each case was 24.3 (IQR 19.6-30.4). Upper respiratory specimens accounted for nearly all specimens submitted (98.8%, n=85,889), the majority (94.0%) of which were NPS (n=81,765)( Table 2) . For respiratory specimens, NPS had the highest proportion of positives (8.8%) compared to TS (4.8% positive). Furthermore, initial NPS-positive specimens were estimated to have a Ct 2.9 (SE=0.5, p<0.001) lower than initial TS-positive specimens after adjusting for symptom status, age and gender ( Table 3) . Lower respiratory specimens such as bronchoalveolar lavage, lung tissue, and sputum, accounted for 0.5% of all specimens. Of the 422 lower respiratory specimens, 38 (9.0%) tested positive with a median Ct value of 27.0 (IQR 22.7-33.4). Nonrespiratory specimens such as cerebral spinal fluid, autopsy tissues, and whole blood, were uncommon (0.01% of all specimens, n=13), and only a single non-respiratory specimen (stool -the only one submitted during the study period) tested positive (Ct 31.9).

We analyzed the results of 5,575 individuals with multiple specimens submitted to provide insight to same-day and multi-day sampling (Figure 1 ). The majority of individuals (86.8%, n=4,837) had 2 specimens collected (Supplementary Table S7 ). Amongst individuals with multiple specimens, 2,632 (45.4%) had all specimens collected on a single day, and 2,874 (49.6%) had one or more specimen collected over a 1-60 day interval. There were 288 (5.0%) individuals with both multiple same-day and multi-day specimens collected.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 26, 2020. ; https://doi.org/10.1101/2020.12.23.20231589 doi: medRxiv preprint

We identified 2,920 individuals with multiple specimens collected on the same day (Figure 1 Furthermore, a larger proportion (39.2%, 1,153/2,943) of individuals with multi-day specimen collection were linked to an outbreak investigation at initial collection compared to those with single day specimens (29.1%, 22,495/77,411; p<0.001).

Of the individuals with multi-day collected specimens, 199 initially tested positive and later tested negative over a period of 1 to 37 days (median 15 days, . The time course of individual tests can be viewed in Figure 4A . We also examined Ct over time for persons with multi-day collection and observed a steady increase in median Ct ( Figure 4B) . For asymptomatic individuals a higher median Ct can be seen for the initial specimen collected compared to symptomatic persons. While this observation was based on a small number of asymptomatic individuals (n=6) with multi-day testing, this finding was further supported by multiple linear regression using all individuals testing positive in the study (persons with single and multi-day specimens). Asymptomatic persons had an estimated 3.0 Ct (SE=0.5, p<0.001) higher compared to symptomatic persons, adjusting for specimen type, age and gender ( Table 3) .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. reviewed Ct values for positive results following an initial negative, and no clear pattern was observed in relation to symptom status or time since collection of the initial negative specimen (Figure 4D) .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 26, 2020. ; https://doi.org/10.1101/2020.12.23.20231589 doi: medRxiv preprint DISCUSSION Molecular-based testing using nucleic acid amplification techniques are currently the gold standard for SARS-CoV-2 detection. These methods can provide high sensitivity and quick turnaround time. Rapid spread of the virus globally created an unprecedented need for increased SARS-CoV-2 diagnostic testing, and consequently a need to establish how and when to best use these tests, and better interpret the results. In this study, we summarized patient data related to laboratory-based COVID-19 diagnosis for 6,834 cases and described diagnostic testing characteristics for more than 86,000 individuals and specimens tested by PHO during the first few months of the pandemic.

We analyzed the characteristics of individuals tested for COVID-19, and as per previous reports (17, 18) , persons testing positive were more likely to be older, with more than 60% of cases aged ≥60 years. Early in the pandemic testing priority was given for persons of any age having travelled to specific regions (19) . However, recommendations were adjusted as the pandemic evolved with COVID-19 symptoms representing the principal reason for testing overall (20) . Of persons reporting symptoms, only 1 in 8 tested positive, which highlights the non-specific nature of COVID-19 symptoms and a major challenge of this pandemic(21).

Our findings of higher positivity and lower Ct values for NPS relative to TS is consistent with the higher clinical sensitivity of NPS reported in the literature (22, 23) . In accordance with current recommendations for, and widespread availability of, NPS, most specimens in this study were upper respiratory. While PHO tested lower respiratory and non-respiratory specimens, these specimen types represented a small proportion of all specimens tested. Interestingly, sputum had a comparatively high positivity (12.9%), similar to previous reports (24) , and may represent an underutilized specimen type in situations where it is warranted. However, interpretations of results for rare specimen types should be made with caution as the reasons for the choice of specimen type collected were not available, and these individuals may have had a higher pre-test probability (25) .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 26, 2020. ; https://doi.org/10.1101/2020.12.23.20231589 doi: medRxiv preprint

Where multiple specimens were collected on the same day, nearly all results were concordant.

In the small number of cases with discordant results, Ct values were often high and the discordance likely represents a level of virus beyond the rRT-PCR limit of detection. This may be related to the time of sampling in the disease course (Ct is lowest within the first week following symptom onset (6)), or poor sample collection (25, 26) . Where specimen type differed for same-day collection, NPS were more often positive, similar to other studies (2, 27) further supporting the use of NPS as the preferred specimen type.

In this study, specimens were collected on different days for nearly 3,000 individuals, with Ct values increasing over disease course and a higher median Ct for asymptomatic persons compared to those with symptoms, similar to previous findings (6, 7, 28) . It should be noted that there have also been reports of similar viral load between symptomatic and asymptomatic individuals (6, 29) . Asymptomatic individuals without epidemiological risk factors (i.e. low pre-test probability) may in some cases represent false positive results. Distinguishing between a true asymptomatic case and a high Ct false positive is a significant diagnostic and public health challenge. Particularly as questions remain regarding the extent of asymptomatic/pre-symptomatic transmission in the community. False negatives also have the potential to complicate efforts in controlling SARS-CoV-2, as these individuals -believed not to be infected -are not directed to isolate and may unknowingly facilitate virus dissemination. In our study, we identified 255 persons with an initial negative test that at a later date tested positive. Of these, nearly three-quarters were initially tested in relation to an outbreak. These individuals may have been truly negative initially -tested as part of screening efforts during an outbreak, and were later exposed due to continued association with the outbreak setting.

Our study has several limitations. First, reported sensitivity and NPV should be interpreted with caution as our analysis does not compare two distinct tests, and instead uses an individual's collective test results within a 7 day period ("true positive" result) as a comparison for their initial test result.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 26, 2020. ; https://doi.org/10.1101/2020.12.23.20231589 doi: medRxiv preprint Therefore, sensitivity was dependent on the time period used as a discrete episode. Current literature reports a 5 day mean incubation with viral shedding a few days before symptom onset. Thus, we defined an episode as 7 days following initial specimen collection, and found our calculation of test sensitivity to be consistent with the literature(2); however, our NPV estimate was higher than other reports (26) . As it is more likely for persons with high pre-test probability to be retested, there may be a bias towards an underestimation of the true sensitivity. The nature of this method does not allow for calculation of specificity and PPV. Second, a limitation of many COVID-19 studies at this time, including this one, is that recommendations regarding who should be tested changed over the study period and may have impacted which individuals were prioritized for testing. Thus, our results may not be representative of all cases, particularly asymptomatic or hospitalized individuals, and may not be generalizable to all locations. Last, drawing conclusions regarding the asymptomatic/pre-symptomatic infected population is difficult within this study population owing to limited data on test requisitions. For example, timing of sample collection in disease course (symptom onset date was often not captured, and is not possible for persons without symptoms) and reason(s) for testing, limited information regarding exposure, and lack of follow-up testing in most cases.

In conclusion, the present study contributes to the rapidly expanding body of knowledge regarding SARS-CoV-2 clinical diagnostics. Our results support existing estimates of test sensitivity while providing further insights into the relationship between Ct and patient-related factors, as well as the variability between specimen types, multiple same-day and repeat testing. Diagnostics has a key role to play in the pandemic, contributing to policy and practice regarding individual-and population-level public health measures used to limit spread of the virus.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 26, 2020. ; https://doi.org/10.1101/2020.12.23.20231589 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 26, 2020. ; https://doi.org/10.1101/2020.12.23.20231589 doi: medRxiv preprint ‡Molecular-based testing included one or more of the following: end-point PCR + Sanger sequencing of the RNA-dependent RNA polymerase (RdRp) gene, rRT-PCR to detect the envelope (E) gene, RdRp gene and/or ORF1ab. §Mann-Whitney U or Chi-square (χ2) test p-value for test result comparison by category. ¶Reasons for testing were not mutually exclusive. #Symptoms-Self-reported response or clinical assessment of fever, cough, sore throat, pneumonia, or other COVID-19 symptoms (12) . **Travel history-Self-reported response to 'Travelled outside the country in the last 14 days?' † †Exposure history-Self-reported response to 'Exposure to probable, or confirmed case?'

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 26, 2020. ; https://doi.org/10.1101/2020.12.23.20231589 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 26, 2020. ; . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 26, 2020. ; https://doi.org/10.1101/2020.12.23.20231589 doi: medRxiv preprint Figure 3 . Comparison of envelope (E) gene rRT-PCR cycle threshold (Ct) values for individuals with multiple same-day specimens collected. Ct values are analyzed by episodes for which there were multiple nasopharyngeal swabs (NPS) collected, or a combination of throat swab (TS) and NPS. Ct is plotted by results category which indicates that the same-day specimens were both positive (concordant), or had a positive specimen and negative specimen (discordant). (A) Boxplot with median Ct for all same-day collected nasopharyngeal swabs (NPS) with concordant results, (B) Ct across sameday collected NPS pairs, (C) boxplot with median Ct for same-day collected NPS and throat specimens with concordant results, (D) Ct across same-day collected NPS and throat specimen pairs. Paired NPS + throat specimens for which the NPS was >3 Ct higher than the throat specimen are shown as pink lines.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 26, 2020. ; https://doi.org/10.1101/2020.12.23.20231589 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 26, 2020. ; https://doi.org/10.1101/2020.12.23.20231589 doi: medRxiv preprint

The authors declare that there are no conflicts of interest.

This study was part of routine laboratory surveillance and thus it was supported through Public Health Ontario's operational funds.

The Public Health Ontario Ethics Review Board has determined that this project did not require research ethics committee approval, as it describes analyses that were completed at Public Health Ontario Laboratory as part of routine clinical respiratory testing during the first wave of the COVID-19 pandemic in Ontario and are therefore considered public health practice.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 26, 2020. ; https://doi.org/10.1101/2020.12.23.20231589 doi: medRxiv preprint

Diagnostic strategies for SARS-CoV-2 infection and interpretation of microbiological results

Sensitivity of nasopharyngeal swabs and saliva for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Virological assessment of hospitalized patients with COVID-2019

Detection of SARS-CoV-2 in Different Types of Clinical Specimens

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. The Lancet

SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients

Viral load of SARS-CoV-2 in clinical samples

Temporal dynamics in viral shedding and transmissibility of COVID-19

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing

COVID-19 Reference Document for Symptoms Version

Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Status of COVID-19 cases in Ontario

Predicting infectious SARS-CoV-2 from diagnostic samples

Epidemiologic and clinical characteristics of 91 hospitalized patients with COVID-19 in Zhejiang, China: a retrospective, multicentre case series

Clinical Characteristics of Covid-19 in New York City

Ontario Ministry of Health and Long-Term Care. COVID-19 -Coronavirus disease

Emergency Planning and Preparedness

COVID-19 Provincial Testing Guidance Update [Internet]. Ontario

Novel Coronavirus Infection (COVID-19) in Humans: A Scoping Review and Meta-Analysis

Nasopharyngeal Swabs Are More Sensitive Than Oropharyngeal Swabs for COVID-19 Diagnosis and Monitoring the SARS-CoV-2 Load

Performance of oropharyngeal swab testing compared to nasopharyngeal swab testing for diagnosis of COVID-19 -United States

SARS-CoV-2 detection in different respiratory sites: A systematic review and meta-analysis

Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients

Clinical Performance of SARS-CoV-2 Molecular Tests

First 12 patients with coronavirus disease 2019 (COVID-19) in the United States

Association of Initial Viral Load in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patients with Outcome and Symptoms

Clinical Course and Molecular Viral Shedding Among Asymptomatic and Symptomatic Patients With SARS-CoV-2 Infection in a Community Treatment Center in the Republic of Korea

We gratefully acknowledge the staff of Virus Detection and Molecular Diagnostics, Public Health Ontario Laboratory, for diagnostic testing of SARS-CoV-2 specimens. We also acknowledge with thanks to the National Microbiology Laboratory (NML), Winnipeg, MB for providing confirmatory and supplementary testing early in the pandemic.